215 related articles for article (PubMed ID: 32445705)
1. ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain.
Kiso T; Watabiki T; Sekizawa T
Eur J Pharmacol; 2020 Aug; 881():173194. PubMed ID: 32445705
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor.
Watabiki T; Tsuji N; Kiso T; Ozawa T; Narazaki F; Kakimoto S
Eur J Pharmacol; 2017 Nov; 815():42-48. PubMed ID: 29017758
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Karbarz MJ; Luo L; Chang L; Tham CS; Palmer JA; Wilson SJ; Wennerholm ML; Brown SM; Scott BP; Apodaca RL; Keith JM; Wu J; Breitenbucher JG; Chaplan SR; Webb M
Anesth Analg; 2009 Jan; 108(1):316-29. PubMed ID: 19095868
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.
Hama AT; Germano P; Varghese MS; Cravatt BF; Milne GT; Pearson JP; Sagen J
PLoS One; 2014; 9(5):e96396. PubMed ID: 24788435
[TBL] [Abstract][Full Text] [Related]
5. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
[TBL] [Abstract][Full Text] [Related]
6. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
Starowicz K; Makuch W; Korostynski M; Malek N; Slezak M; Zychowska M; Petrosino S; De Petrocellis L; Cristino L; Przewlocka B; Di Marzo V
PLoS One; 2013; 8(4):e60040. PubMed ID: 23573230
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M
Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580
[TBL] [Abstract][Full Text] [Related]
10. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
11. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW
Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291
[TBL] [Abstract][Full Text] [Related]
12. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
Mol Pain; 2016; 12():. PubMed ID: 27178246
[TBL] [Abstract][Full Text] [Related]
13. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
Adamson Barnes NS; Mitchell VA; Kazantzis NP; Vaughan CW
Br J Pharmacol; 2016 Jan; 173(1):77-87. PubMed ID: 26398331
[TBL] [Abstract][Full Text] [Related]
14. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Slivicki RA; Xu Z; Mali SS; Hohmann AG
Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
[TBL] [Abstract][Full Text] [Related]
15. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
16. Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats.
Jee Kim M; Tanioka M; Woo Um S; Hong SK; Hwan Lee B
Mol Pain; 2018; 14():1744806918814345. PubMed ID: 30380982
[TBL] [Abstract][Full Text] [Related]
17. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
Murai N; Hiyama H; Kiso T; Sekizawa T; Watabiki T; Oka H; Aoki T
Neuropharmacology; 2017 Nov; 126():97-107. PubMed ID: 28859883
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.
Schaffler K; Yassen A; Reeh P; Passier P
Pain Med; 2018 Jun; 19(6):1206-1218. PubMed ID: 29228247
[TBL] [Abstract][Full Text] [Related]
19. The MOBILE Study-A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain.
Bradford D; Stirling A; Ernault E; Liosatos M; Tracy K; Moseley J; Blahunka P; Smith MD
Pain Med; 2017 Dec; 18(12):2388-2400. PubMed ID: 28383710
[TBL] [Abstract][Full Text] [Related]
20. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents.
Griebel G; Stemmelin J; Lopez-Grancha M; Fauchey V; Slowinski F; Pichat P; Dargazanli G; Abouabdellah A; Cohen C; Bergis OE
Sci Rep; 2018 Feb; 8(1):2416. PubMed ID: 29403000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
